Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Madrid-Gambin, Francisco
- dc.contributor.author Fabregat-Safont, David
- dc.contributor.author Gómez Gómez, Àlex
- dc.contributor.author Olesti Muñoz, Eulàlia, 1991-
- dc.contributor.author Mason, Natasha L.
- dc.contributor.author Ramaekers, Johannes G.
- dc.contributor.author Pozo Mendoza, Óscar J., 1975-
- dc.date.accessioned 2024-10-01T06:31:49Z
- dc.date.available 2024-10-01T06:31:49Z
- dc.date.issued 2023
- dc.description.abstract Psychedelics are classical hallucinogen drugs that induce a marked altered state of consciousness. In recent years, there has been renewed attention to the possible use of classical psychedelics for the treatment of certain mental health disorders. However, further investigation to better understand their biological effects in humans, their mechanism of action, and their metabolism in humans is needed when considering the development of future novel therapeutic approaches. Both metabolic and metabolomics studies may help for these purposes. On one hand, metabolic studies aim to determine the main metabolites of the drug. On the other hand, the application of metabolomics in human psychedelics studies can help to further understand the biological processes underlying the psychedelic state and the mechanisms of action underlying their therapeutic potential. This review presents the state of the art of metabolic and metabolomic studies after lysergic acid diethylamide (LSD), mescaline, N,N-dimethyltryptamine (DMT) and β-carboline alkaloids (ayahuasca brew), 5-methoxy-DMT and psilocybin administrations in humans. We first describe the characteristics of the published research. Afterward, we reviewed the main results obtained by both metabolic and metabolomics (if available) studies in classical psychedelics and we found out that metabolic and metabolomics studies in psychedelics progress at two different speeds. Thus, whereas the main metabolites for classical psychedelics have been robustly established, the main metabolic alterations induced by psychedelics need to be explored. The integration of metabolomics and pharmacokinetics for investigating the molecular interaction between psychedelics and multiple targets may open new avenues in understanding the therapeutic role of psychedelics.
- dc.format.mimetype application/pdf
- dc.identifier.citation Madrid-Gambin F, Fabregat-Safont D, Gomez-Gomez A, Olesti E, Mason NL, Ramaekers JG, et al. Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans. Biomed Pharmacother. 2023 Dec 31;169:115775. DOI: 10.1016/j.biopha.2023.115775
- dc.identifier.doi http://dx.doi.org/10.1016/j.biopha.2023.115775
- dc.identifier.issn 0753-3322
- dc.identifier.uri http://hdl.handle.net/10230/61279
- dc.language.iso eng
- dc.publisher Elsevier
- dc.relation.ispartof Biomed Pharmacother. 2023 Dec 31;169:115775
- dc.rights © 2023 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.subject.keyword Ayahuasca
- dc.subject.keyword Dimethyltryptamine
- dc.subject.keyword Lysergic acid diethylamide
- dc.subject.keyword Metabolism
- dc.subject.keyword Metabolomics
- dc.subject.keyword Psilocybin
- dc.subject.keyword Psychedelics
- dc.title Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion